Department of Neurology, The Ohio State University, 395 W 12th Ave #7, Columbus, OH 43210, USA.
Department of Pharmacy, The Ohio State University, Columbus, OH, USA.
J Stroke Cerebrovasc Dis. 2020 Jul;29(7):104865. doi: 10.1016/j.jstrokecerebrovasdis.2020.104865. Epub 2020 May 11.
We present what may be the first case report of acute thrombocytopenia after tissue plasminogen activator (tPA) in the setting of stroke. Early fibrinogen degradation coagulopathy (EFDC) after tPA has been described in the past and acute thrombocytopenia may fall into this spectrum. Further studies are needed to evaluate the bleeding and mortality risk associated with thrombocytopenia after tPA.
我们呈现的可能是首例组织型纤溶酶原激活剂（tPA）治疗后发生的急性血小板减少症病例报告。tPA 治疗后早期纤维蛋白原降解性凝血障碍（EFDC）已有描述，而急性血小板减少症可能属于这一范畴。需要进一步研究来评估 tPA 治疗后血小板减少症相关的出血和死亡率风险。
